Mounjaro 2.5mg vs 5mg: what the evidence says about moving up

What the licensed titration schedule actually says

Tirzepatide's UK prescribing information (as set out in the Mounjaro Summary of Product Characteristics on the eMC) describes a specific sequence. Treatment opens at 2.5mg for four weeks. After that, the prescriber typically moves patients to 5mg for a further four weeks before considering the next step upward. The schedule continues in 2.5mg increments: 7.5mg, then 10mg, 12.5mg and, for those who need it, 15mg.

The 2.5mg pen has no independent weight-loss target. Its job is tolerance. Nausea, constipation and fatigue tend to peak when the body first meets a new GLP-1/GIP agonist; the lower starting dose keeps that manageable. The 5mg pen is the first dose the clinical programme studied as a sustained therapeutic level. That distinction matters when you are trying to understand what each pen is actually doing.

Timing the move between doses sometimes collides with real life: a holiday, a busy stretch at work, payday falling awkwardly. A prescriber at a regulated service will look at your response (not just the calendar) before confirming the switch. For a closer look at what staying on 2.5mg longer looks like in practice, our 2.5mg page covers the detail.

Trial data: what 5mg produces compared with the starting dose

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across three tirzepatide doses (5mg, 10mg and 15mg) against placebo over 72 weeks. Participants on 5mg achieved an average body-weight reduction of around 15% from baseline. That is roughly half the result seen at 15mg (approximately 20–21%), but still a substantial outcome at a dose many people reach after their first eight weeks of treatment.

Those numbers are population averages from a controlled trial setting. Individual results depend on adherence, diet, activity and biology. The data does, though, make one thing clear: 5mg is not a halfway house. It is a clinically active dose with a meaningful evidence base behind it.

How weight loss actually compares across the two doses is covered in more depth elsewhere on the site, including what the trial data means in practical terms for people in the early stages of treatment.

Side-effect profile: does anything change at 5mg?

The short answer is: the same side effects, sometimes at a somewhat higher rate. The most frequently reported effects across the SURMOUNT programme were gastrointestinal, nausea, loose stools, constipation, reflux and reduced appetite. In SURMOUNT-1, GI events were more common at higher doses, and the 5mg group sat between the placebo and 10mg groups in frequency. For most people, symptoms are most noticeable in the first one to two weeks after a dose increase and tend to settle.

The MHRA recommends that patients and clinicians stay alert to signs of pancreatitis: severe, persistent stomach pain that may radiate to the back. That signal applies at any dose; the regulator issued a Drug Safety Update for GLP-1 medicines in January 2026 reinforcing this. Any suspected side effect can be reported through the Yellow Card scheme at yellowcard.mhra.gov.uk.

The broader side-effect picture for tirzepatide (including what to watch for and when to call a prescriber) is on the main Mounjaro information page.

2.5mg vs 5mg at a glance

*Source: SURMOUNT-1, NEJM. Trial figures are population averages in a controlled setting; individual outcomes vary.

Which dose is right for you at any given point is a clinical decision our prescribers make with you, based on your response, tolerance and health picture. If you would like a side-by-side breakdown of how the starter pen and the first therapeutic dose differ, our guide comparing Mounjaro 2.5mg and 5mg sets that out clearly. If you are thinking about what comes after 5mg, our comparison of 5mg and 7.5mg covers that step. And for context on the cost of treatment across doses, the prices page sets out what private prescriptions typically look like in the UK.